The FDA’s new approval for KERENDIA in chronic kidney disease linked to type 1 diabetes puts Bayer (XTRA:BAYN) back in focus for investors watching its pharmaceuticals pipeline.
The latest KERENDIA approval lands at a time when Bayer’s momentum has been picking up, with a 90 day share price return of 24.93% and a 1 year total shareholder return of 80.30% off a current share price of €49.46. This points to sentiment that has strengthened meaningfully as the pharmaceuticals pipeline, new oncology approvals and recent biofuels partnerships have come into sharper focus.
Scan for other healthcare and pharma plays showing similar momentum by reviewing the hand picked 132 healthcare AI stocks that are drawing attention for their pipelines and data driven approaches.
Bulls see Bayer’s KERENDIA win and oncology progress as the start of a reset. Bears point to recent losses and legal overhangs. Which side does the current valuation lean toward?
Most Popular Narrative: 15% Undervalued
Analysts following Bayer see fair value at €58.22 against a last close of €49.46. This frames the recent share price strength as only a partial move toward that narrative target rather than the end of the rerating story.
Bayer's strategic focus on portfolio optimization and disciplined divestitures, coupled with digital transformation, enhanced customer-centricity, and an R&D-rich environment, underpins a shift toward higher-value, less volatile market segments. This increases the resilience and quality of future earnings and improves net margin over time.
See why 158 investors see Bayer as 15% undervalued.
Result: Fair Value of €58.22 (UNDERVALUED)
Still, the Bayer story can change quickly if glyphosate and PCB litigation costs exceed current provisions, or if pressure on key crop protection products intensifies.
Find out about the key risks to this Bayer narrative.
Next Steps
If the tone of this Bayer story feels conflicted, now is the time to pressure test the numbers yourself and decide where you stand. To see which rewards currently have investors optimistic, review the 3 key rewards.
Looking for more Bayer investment ideas?
If you are serious about pressure testing Bayer against other options, do not stop at one ticker. Use curated screeners to spot opportunities others overlook.
- Target value with quality by reviewing the 170 high quality undervalued stocks that combine stronger cash flows with sturdier balance sheets.
- Prioritise resilience by scanning the 230 resilient stocks with low risk scores that score well on financial strength and business stability.
- Hunt for tomorrow’s potential leaders by checking the 615 high quality undiscovered gems that still sit off most investors’ radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com